Current insights into the implications of m6A RNA methylation and autophagy interaction in human diseases

Xuechai Chen, Jianan Wang, Muhammad Tahir, Fangfang Zhang, Yuanyuan Ran, Zongjian Liu* and Juan Wang*

Abstract

Autophagy is a conserved degradation process crucial to maintaining the primary function of cellular and organismal metabolism. Impaired autophagy could develop numerous diseases, including cancer, cardiomyopathy, neurodegenerative disorders, and aging. N6-methyladenosine (m6A) is the most common RNA modification in eukaryotic cells, and the fate of m6A modified transcripts is controlled by m6A RNA binding proteins. m6A modification influences mRNA alternative splicing, stability, translation, and subcellular localization. Intriguingly, recent studies show that m6A RNA methylation could alter the expression of essential autophagy-related (ATG) genes and influence the autophagy function. Thus, both m6A modification and autophagy could play a crucial role in the onset and progression of various human diseases. In this review, we summarize the latest studies describing the impact of m6A modification in autophagy regulation and discuss the role of m6A modification-autophagy axis in different human diseases, including obesity, heart disease, azoospermatism or oligospermatism, intervertebral disc degeneration, and cancer. The comprehensive understanding of the m6A modification and autophagy interplay may help in interpreting their impact on human diseases and may aid in devising future therapeutic strategies.

Keywords: m6A, RNA methylation, Autophagy, Obesity, Azoospermatism, Ischemic heart disease, Cancer

Background

Autophagy is an evolutionarily conserved mechanism that widely occurs in eukaryotic organisms. It attracted increasing attention due to its significant role in cell survival (during the state of energy or nutrient deficiency) and removing dysfunctional or unnecessary organelles and proteins [1]. In humans, aberrant autophagy regulation could develop various pathophysiological conditions, including cancer, aging, neurodegenerative disorders, and cardiomyopathy [2]. Autophagy occurs in three different forms: macro-autophagy, micro-autophagy, and chaperone-mediated autophagy (CMA) [3]. All the three forms follow the autophagy-lysosomal pathway (ALP), in which cytosolic material is transported to lysosomes for degradation. In macro-autophagy, autophagosome containing cytosolic components transports to the lysosome. Following its attachment to the lysosome, cytosolic components are degraded. In micro-autophagy, lysosomal membrane invaginates and cytoplasmic components are engulfed directly by the lysosome and degraded. In CMA, chaperone proteins (such as Hsc-70) make a complex with target proteins and enable their entry into the lysosome through the lysosomal-associated membrane

*Correspondence: liuzj888@ccmu.edu.cn; juanwang@bjut.edu.cn
1 Center of Excellence for Environmental Safety and Biological Effects, Beijing International Science and Technology Cooperation Base for Antiviral Drugs, Faculty of Environment and Life, Beijing University of Technology, 100 Ping Le Yuan, Chaoyang District, Beijing 100124, People’s Republic of China
2 Department of Rehabilitation, Beijing Rehabilitation Hospital, Capital Medical University, Xixiazhuang, Badachu, Beijing 100144, People’s Republic of China

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
protein 2A (LAMP-2A) receptor. Following entry, target proteins are finally degraded [4].

Macro-autophagy (henceforth referred to as autophagy) is the most prevalent form of autophagy (Fig. 1A). It starts with the formation of autophagosome (double-membrane-bound vesicle), which harbors the target cellular components. Autophagosomes deliver the unwanted cellular components to the lysosome for degradation by lysosomal hydrolases. Numerous autophagy-related (ATG) genes regulate this whole process. Several factors contribute to initiating the cytoprotective autophagy process. Nutrient deficiency, oxygen depletion, and harmful proteins produce stress condition, which inactivates the mTOR (mammalian target of rapamycin) complex. Therefore, Unc-51 like kinase 1/2 (ULK1/2) is activated. The activated ULK1/2 kinase promotes the binding of the focal adhesion kinase family interacting protein of 200 kDa (FIP200) to the ATG13 protein. ATG13-FIP200 complex further phosphorylates ULK proteins. Subsequently, ATG13-FIP200 complex and phosphorylated ULK proteins recruit more ATG proteins and facilitate the formation of double-membrane autophagosome [5–8]. Afterwards, the autophagosome moves to the lysosome with the help of microtubule proteins. LC3-II is one of the LC3 (microtubule-associated protein 1A/1B-light chain 3) proteins. It facilitates the fusion of the autophagosome to the lysosome to form autolysosomes, and this dynamic process is called autophagic flux [9].

Many studies indicate that epigenetic modifications such as DNA methylation, histone modifications and RNA modifications play a vital role in autophagy regulation [10, 11] (Fig. 1B). Such modifications can directly influence the expression of ATG genes or interfere with signaling mechanisms that regulate autophagy.

N6-methyladenosine (m6A), characterized by adenosine methylation at nitrogen 6 position, is one of the most profound post-transcriptional modifications. It

![Fig. 1](image-url)  
**Fig. 1** The process of macro-autophagy and its epigenetic regulation. **A** Autophagy is initiated with the formation of ULK1 complex (ULK1-ATG13-FIP200). BECN1, ATG14 and PI3K complex facilitate the formation of phagophore. ATG5-ATG12-ATG16 complex and PE-conjugated-LC3II promote phagophore elongation and autophagosome formation. Autophagosome fusion with the lysosome results in the degradation of target molecules. **B** Epigenomic modifications in DNA, RNA, and histones regulate autophagy by modifying the expression of autophagy-related genes or affecting the autophagy-associated signaling pathways
commonly occurs in mRNAs and long non-coding RNAs (lncRNAs) in higher eukaryotes and is considered the predominant internal modification in RNA. m6A functionally regulates the eukaryotic transcriptome by influencing mRNA splicing, export, subcellular localization, translation, stability, and decay. Thus, aberrant m6A methylation could modulate biological processes and develop human diseases [12].

Recently, one report showed that the post-transcriptional regulation of Atg1/ULK1 could be altered by m6A RNA modification, resulting in autophagy inhibition [13]. Thereafter, many studies demonstrated the effects of m6A modification in the autophagy mechanism [14–16]. In some cases, the m6A modification imparts direct inhibitory effects on autophagy [17]. It could also affect the formation of autophagosomes to dysregulate autophagy [18]. Sometimes it could promote autophagy initiation [19]. The current data shows that the m6A modification plays a crucial role in regulating autophagy. Moreover, the effects of the m6A modification on autophagy are disease context-dependent. Since both m6A modification and autophagy play critical roles in regulating health conditions, this review summarizes the inferences of the latest studies, which explored the effects of m6A modification and autophagy interactivity on human diseases, including obesity, heart disease, fertility disorders, intervertebral disc degeneration, and cancer. A comprehensive understanding of the m6A and autophagy relationship in human diseases may benefit in devising therapeutic strategies in the future.

![Diagram of m6A RNA modification and its role in RNA metabolism.](image)

**Fig. 2** The dynamic and reversible m6A RNA modification and its role in RNA metabolism. m6A RNA methylation is exerted by methyltransferases (METTL3, METTL14, WTAP, etc.), removed by demethylases (FTO and ALKBH5). mRNA processing, splicing, stability, translation, and subcellular localization can be influenced by m6A modification through the actions of m6A binding proteins.
Reversible/dynamic m6A RNA methylation in autophagy modulation

It is observed that one-fourth of the cellular transcriptome contains multiple m6A modification residues [20, 21]. Furthermore, it is identified that the RRACH motif (R=A or G, H=A, C, or U) in RNA is the primary site for m6A modification [22–24]. The m6A modification is dynamic and reversible and is regulated by various protein complexes [25, 26]. m6A modification is exerted by methyltransferases (Writers) [27, 28], eliminated by demethylases (Erasers) [29, 30], and recognized by m6A binding proteins (Readers) (Fig. 2).

m6A modification and its regulatory enzyme complexes play an important role in the mRNA life cycle. Methyltransferases commonly exerting m6A modification include methyltransferase-like 3 (METTL3), methyltransferase like-14 (METTL14), vir-Like m6A methyltransferase associated (VIRMA, KIAA1429), RNA binding motif protein 15 (RBM15), and Wilms’ tumor 1-associated protein (WTAP) [31, 32]. m6A methylation process is initiated when METTL14 binds to METTL3 to constitute a stable heterodimer core complex [33]. METTL3/ METTL14 methyltransferase complex and WTAP carry out the deposition of m6A on nuclear RNA in mammalian cells [28]. Studies reported that RBM15 and KIAA1429 facilitate the METTL3/ METTL14/ WTAP complex to induce m6A modification. Decreased KIAA1429 and RBM15 protein levels reduced the deposition of m6A on mRNA [34, 35]. This finding is suggestive of their critical role in the methylation process. Besides, other methyltransferases were also discovered recently, such as METTL16 works independently to induce m6A deposition on nuclear RNA [32], and METTL5 induces m6A on ribosomal RNA [36].

m6A modification is reversible due to the two demethylases, including fat mass and obesity-associated protein (FTO) and alpha-ketoglutarate-dependent dioxygenase alkB homolog 5 (ALKBH5) proteins. These are mainly present in the nuclear compartments [29, 30]. As identified for the first RNA demethylase, FTO removes methyl group of m6A and is essential for mRNA processing. ALKBH5 could also eliminate m6A modification from mRNA. It also has a profound role in nuclear RNA export and metabolism [30, 37].

Proteins are defined as “Readers”, which selectively bind to m6A modified sites on mRNA. Readers regulate m6A modification by altering the recognition of modified mRNA [38]. YTH-domain N6-methyladenosine RNA-binding proteins (YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2) are the prominent reader proteins. YTHDF1 enhances m6A mRNA translation by promoting ribosome assembly and making interaction with the initiation factor. YTHDF2 attenuates the stability of m6A RNA and promotes its degradation by directing it to processing bodies (P bodies) in the cytoplasm. YTHDF3 facilitates YTHDF1 and YTHDF2 to execute their functions [39–44]. YTHDC1 regulates pre-mRNA splicing and RNA exportation, while YTHDC2 directly interacts with ribosome subunits. Hence, it interferes with mRNA translation. Besides the YTH-domain protein family, other proteins such as insulin-like growth factor 2 mRNA-binding proteins (IGF2BP) also bind to m6A modified sites and enhance mRNA stability [45].

Therefore, “Writers”, “Erasers”, and “Readers” dynamically regulate m6A modification. Being the most abundant mRNA modification, m6A could modulate various biological processes, including autophagy.

Autophagy is a lysosome-assisted degrading mechanism that helps the cells to cope with stress conditions [46, 47]. Recently, several studies determined the potent role of m6A modification in autophagosome formation and autophagy regulation [48]. m6A modification could influence the transcriptional regulation of ATG proteins and affect the autophagy mechanism.

The mechanistic target of rapamycin complex 1 (mTORC1) could inhibit autophagy through phosphorylation of Atg13. A report showed that mTORC1 could activate the chaperon containing tailless complex poly-peptide 1 (CCT) to stabilize methyltransferase complex (METTL3/ METTL14). As a result, m6A levels increased on the mRNAs of ATG genes, and the transcripts of these genes became highly susceptible to degradation. Hence autophagy is suppressed [49]. Moreover, another study revealed that decreased levels of METTL14 contribute to promoting autophagy in Leydig cells (LCs) [48]. This study showed that reduction in METTL14 levels provided stability to the mRNA of calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2). Subsequently, CAMKK2 activated the adenosine 5-monophosphate-activated protein kinase (AMPK) and ULK1 complex (positive regulators of autophagy), which initiated the autophagy. FTO demethylase was also observed to promote autophagy by splitting ULK1 from YTHDF2, thus increased ULK1 expression [13]. Observations in ovarian cancer cells showed that ALKBH5 inhibits autophagy. Reduction in ALKBH5 expression resulted in degradation of BCL-2 mRNA. Consequently, the BCL-2-Bclin1 complex (negative regulators of autophagy) was disrupted, and autophagy was activated [50].

Upon FTO depletion, m6A modification of ATG7 and ATG5 mRNAs happens directly, which provides a basis for binding YTHDF2 protein to the ATG transcripts. This binding ultimately dysregulates the autophagosome assembly [18]. It is also reported that upregulation of METTL3 induced methylation and triggered the binding of YTHDF1 to forkhead box class O3 (FOXO3)
transcripts and provided stability to the FOXO3 mRNA. Hereafter, FOXO3 halted the expression of ATG genes to inhibit autophagy [51]. Furthermore, METTL3 mediated m6A modification of transcription factor EB (TFEB) mRNA resulted in its binding to m6A reader protein heterogeneous nuclear ribonucleoprotein D (HNRNPD). TFEB is considered a major transcriptional regulator of lysosome biosynthesis and autophagy. The binding of HNRNPD to TFEB reduced TFEB levels, which resulted in decreased lysosome biosynthesis and impaired autophagy [17, 47, 52].

As one of the most prevalent RNA modifications, m6A plays an important role in the regulation of the stability and translation of mRNAs, and is involved in various bioprocesses. m6A RNA modification could regulate autophagy by modifying the expression of ATG genes or affecting the autophagy-associated signaling pathways, hence regulates various physiological and pathological processes. Taken together, the influence of the m6A modification on autophagy is complex and dynamic, and its regulatory mechanism needs to be further determined.

**m6A-autophagy regulation in metabolic related diseases**  
**Role of m6A modification and autophagy interactivity in adipogenesis and obesity**

For the last few decades, obesity and its related disorders are emerging worldwide [53, 54]. Obesity is characterized as an irregular or unhealthy accumulation of adipose tissue due to an increase in adipocyte volume (hypertrophy) or amount of fatty tissue (hyperplasia). Several studies confirmed that numerous biological processes control adipogenesis, including transcriptional mechanisms, and epigenetic alterations [55].

As the most prevalent eukaryotic mRNA modification, m6A could influence adipogenesis [56–59]. FTO plays a critical role in regulating fat mass and body weight, and m6A levels are inversely linked to adipocyte differentiation [60, 61]. Likewise, autophagy is also known to regulate fat mass accumulation and lipogenesis [62]. Empirical evidence suggests that obesity could occur due to compromised autophagy [63, 64]. Excessive consumption of nutrients promotes obesity and triggers mTORC1 activity. Consequently, the synthesis of many ATG proteins is inhibited, which leads to the suppression of autophagy [65]. It is also reported that adipose tissue mediated lysosomal dysfunction could cause autophagosome retention and lower autophagic clearance [66].

Numerous studies have examined the interaction between FTO and autophagy. FTO can act as an amino acid sensor, and it can significantly improve the functioning of mTORC1 and regulate autophagy [67–69]. Aas et al. showed that autophagy remained unaffected in response to upregulation of FTO in nutrients depleted U2OS cells [70]. On the contrary, research conducted in MEF cells exhibited that arsenic-mediated upregulation of FTO inhibited autophagy, and autophagy inhibition could increase the stability of

![Fig. 3](image)

**Fig. 3** Effects of m6A-autophagy interaction in metabolic related diseases. A FTO-mediated demethylation provides stability to ATG5 and ATG7 transcripts. Subsequently, autophagy is induced, which promotes adipogenesis and obesity. B m6A mediated reduction in AMPK (AMP-activated protein kinase) activity resulted in autophagy inhibition. Consequently, testosterone synthesis decreased, which mediated azoospermtism or oligospermatism.
FTO [71]. Previously, it also reported that FTO knockdown in Hela cells could inhibit autophagy by downregulating the expression of ULK1 [13]. Taken together, the diversified role of autophagy attributes to producing various outcomes in different tissues or cells. The variations in FTO-mediated autophagy could presumably be asserted by the specific form or state of cells used in the experiments.

One recent study in adipocytes reported that ATG5 and ATG7 proteins play a vital regulatory role in FTO-mediated autophagy (Fig. 3A) [18]. ATG7 conducts ATG12-ATG5 covalent binding via a ubiquitin-like conjugation mechanism. The resulting ATG12-ATG5 homodimer attaches to ATG16L and facilitates autophagosome elongation [72, 73]. It is observed that FTO depletion decreased the ATG12-ATG5 covalent binding, reduced ternary complex development, and attenuated the autophagy activation. This FTO-mediated attenuation of autophagy and ATG genes expression is observed to be associated with m6A modification [18].

On the contrary, a recent study reported that FTO has no impact on ULK1 protein levels in preadipocytes [18]. This result contradicts the findings reported in a previous study in HEK293T cells, which showed FTO could alter the ULK1 protein levels [13]. The study in preadipocytes exhibited that FTO knockdown or overexpression failed to alter the ULK1 protein levels. Moreover, this study reported that YTHDF2 overexpression reduced the autophagy-related protein levels by targeting the m6A-modified mRNAs of ATG genes. Forced expression of YTHDF2 failed to regulate ULK1 mRNA or protein levels and autophagy in preadipocytes. The reason for this outcome might be the inability of YTHDF2 to recognize ULK1 mRNA in adipocytes specifically. These outcomes exhibited that FTO-mediated alterations in m6A modification and activity of YTHDF2 influence the expression of ATG proteins and autophagy process in cell type-specific manner [18].

The findings provide an understanding of m6A, and autophagy regulated mechanisms of adipogenesis. These could benefit in identifying targets to combat obesity and its associated health issues.

Role of m6A modification and autophagy interplay in male fertility disorders

Spermatogenesis is a complex process responsible for the morphological and biochemical changes in spermatogenic stem cells (SSCs), which develop into elongated mature spermatozoa. Spermatogenesis is regulated through numerous transcriptional, posttranscriptional, and translational processes [74]. Many hormones perform their vital role in spermatogenesis, especially testosterone plays a crucial role in this process [75, 76]. The Leydig cells (LCs) found in the testis interstitium are the primary site for the synthesis of testosterone in males. In the absence of testosterone, spermatogenesis halts at the meiosis stage. Thus, deficiency of testosterone could cause degeneration of germ cells at post meiosis. Furthermore, mature sperms could stay within the Sertoli cells, leading to azoospermia, oligospermia, or infertility.

Literature review revealed that autophagy is a critical regulatory process in testosterone synthesis and spermatogenesis [77, 78]. Huang et al. demonstrated that autophagy core protein ATG5 is vital for male fertility due to its role in spermatogenesis [79]. Autophagy begins in the forerunner LCs, is steadily enhanced with LCs differentiation, and culminated in mature LCs. These findings imply that autophagy activity constantly changes during LCs differentiation.

Emerging evidence shows that m6A alteration could affect the gene expression in male germine cells [80, 81]. Recently, a study showed that m6A modification levels steadily decreased in LCs during their transformation from stem LCs into mature LCs. This finding indicates a potential role of m6A in LCs differentiation. Furthermore, this study also showed that m6A could negatively impact autophagy in LCs [48]. m6A modification was observed to attenuate ULK1 and TFEB (transcriptional regulators of autophagy) mRNA levels, which resulted in autophagy inhibition in LCs [13, 17].

In a recent study, LCs were treated with human chorionic gonadotropin (HsCG) to investigate autophagy dependency on AMPK-ULK1. The upstream kinases such as STK11/LKB1 and CAMKK2 could increase, and PPM1A phosphatase could reduce the phosphorylation of AMPK. HsCG treatment in LCs enhanced the expression of CAMKK2 kinase and reduced the level of PPM1A phosphatase, which facilitated the activation of PRKAA2 mediated autophagy (Fig. 3B) [48]. Further experiments demonstrated that m6A could interfere with PRKAA2 activity by enhancing PPM1A translation and CAMKK2 mRNA degradation in an m6A-dependent manner [48]. HsCG treatment caused a reduction in m6A modification on CAMKK2 and PPM1A transcripts, which resulted in decreased PPM1A levels and increased CAMKK2 levels. Moreover, upregulation of PPM1A and depletion of CAMKK2 resulted in attenuation of HsCG-triggered autophagy in LCs. This finding suggests that both PPM1A and CAMKK2 are essential for autophagy induction, and synchronized regulation of these proteins could provide a possibility to control testosterone synthesis.

m6A modification could alter testosterone synthesis and develop oligospermia or azoospermia. These findings emphasize the essential role of m6A RNA modification in the regulation of autophagy and testosterone synthesis. These findings suggest that new therapeutic strategies
can be developed by targeting m6A RNA modification in patients with testosterone deficiency, azoospermia, and oligospermia.

**m6A-autophagy regulation in apoptosis-induced diseases**

**Role of m6A modification and autophagy interactivity in cardiomyocytes apoptosis and ischemic heart disease**

Cardiovascular diseases (CVDs) are among the common causes of human illness and death in the world. Several studies reported irregular m6A methylation could promote CVDs incidence, including ischemic heart disease, cardiac arrest, cardiac hypertrophy [82, 83]. It is observed that autophagosome formation increases during ischemia and reperfusion, and the AMPK might be responsible for this increment [84]. Trehalose (a disaccharide) upregulates TFEB and stimulates autophagy, and prevents cardiomyocyte apoptosis [85]. Cardiomyocytes can keep their mitochondria healthy by mitophagy, which protects the heart from ischemic injury [86]. This data suggest that autophagy could prevent ischemic heart disease, but the underlying molecular mechanisms still need to be elucidated.

m6A may be a new starting point to analyze the regulatory processes of autophagy in heart disease (Fig. 4A). Previous studies showed that the FTO-dependent m6A pathway plays a critical role in cardiac remodeling and restoration [87]. Song et al. investigated the function of m6A regulated autophagy in hypoxia/reoxygenation (H/R) cardiac muscle cells [17]. m6A modification significantly increased in H/R-treated cardiomyocytes and ischemia/reperfusion (I/R)-treated mice heart, and it occurred due to the elevated expression of METTL3 and decreased expression of ALKBH5. METTL3 is highly expressed in cardiomyocytes during H/R therapy, which could interfere with autophagic flux in the cardiomyocytes. METTL3 mediated increased m6A modification caused HNRNPD binding to TFEB pre-mRNA and reduced its stability. As a result, the TFEB level decreased. TFEB is a key regulator of autophagy [88].

![Diagram](image.png)

**Fig. 4** Effects of m6A-autophagy interaction in apoptosis-induced diseases. **A** Hypoxia/Reoxygenation (H/R) mediated increased m6A modification could provide stability to TFEB transcripts, promoting autophagy and inhibiting apoptosis of cardiomyocytes. On the contrary, HNRNPD could reduce TFEB mRNA stability which could result in autophagy inhibition and apoptosis induction in cardiomyocytes. **B** YTHDF2 mediated degradation of FIP200 mRNA causes autophagy inhibition and apoptosis induction in NPCs. BSMCs-NPCs co-culturing could induce autophagy which prevents apoptosis of NPCs.
Its deficiency could reduce autophagy activity in cardiomyocytes, resulting in increased apoptosis in these cells [89]. Song et al. reported that METTL3 depletion in H/R-treated cardiomyocytes might improve cell viability. This finding suggests that the targeted inhibition of METTL3 may provide new avenues to formulate therapeutic strategies for cardiovascular diseases.

**Role of m6A modification and autophagy interplay in apoptosis of nucleus pulposus cells and intervertebral disc degeneration**

Degenerative changes in nucleus pulposus cells (NPCs) could cause degeneration of the intervertebral disc (IVD). It is thought to be the most common cause of back pain. Studies showed that autophagy could reduce NPCs' degenerative changes, thus minimizing the risk of IVD degeneration [90].

Li et al. recently reported that bone marrow-derived mesenchymal stem cells (BMSCs) could promote autophagy and reduce apoptosis in NPCs by modulating m6A modification in a co-culture model [91]. During IVD degeneration, m6A modification of FIP200 mRNA occurs. YTHDF2 binds to m6A modified FIP200 transcripts and degrades them. BMSCs and NPCs co-culturing resulted in enhanced AKLBH5 expression, which demethylated the FIP200 mRNAs and prevented their degradation. Furthermore, the reduction in m6A modification of FIP200 mRNA led to a decrease in their YTHDF2-mediated degradation. Consequently, autophagy activity was enhanced, which reduced the risk of apoptosis in NPCs in the co-culture model. The findings offer a novel theoretical basis for reversing IVD degeneration (Fig. 4B).

**m6A-autophagy regulation in cancer**

**Role of m6A modification and autophagy interactivity in cancer progression**

Increasing evidence shows that m6A modification is associated with multiple human cancers, including breast cancer, lung cancer, and glioblastoma [92]. Autophagy is an intracellular clearance mechanism that is regulated by numerous proteins. It is observed to promote metastasis.

![Fig. 5 Effects of m6A-autophagy interaction in cancer progression. A HIF-1α induced YTHDF1 expression promotes ATG2A and ATG14 translation. Subsequently, autophagy is activated, which could promote HCC progression. B m6A provides stability to UBE2C transcripts, which could inhibit autophagy. Consequently, the proliferation, clonal expansion, and invasive growth of NSCLC are promoted. C IGFBP2 mediated increased stability of MYC mRNA promotes glycolysis and cancer cell proliferation in CRC. D Autophagy-mediated upregulation of FTO could increase the stability of PD-1, CXCR4, SOX10 transcripts and which can promote the progression of melanoma.](image)
of malignant tumor cells. mTOR is a vital regulator of autophagy. mTOR is also a downstream target of the phosphatidylinositol 3-kinase (PI3K) and kinase AKT pathways. In endometrial cancer, m6A modification regulates AKT activity, which indicates that m6A can potentially influence mTOR regulation through the AKT signaling pathway [93]. However, the exact mechanism of coordination between m6A modification and autophagy and its effects on cancer progression need to be further explored.

It is well known that hypoxia could promote the development and progression of cancers. Hypoxia can induce autophagy, which can help the cancer cells to cope with hypoxic conditions. Recently, a study reported that m6A reader YTHDF1 could promote hypoxia-induced autophagy, which in turn facilitated the development of human hepatocellular carcinoma (HCC) [94]. In hypoxia stress, HIF-1α can induce YTHDF1 expression, which promoted the translation of ATG2A and ATG14 in an m6A-dependent manner. The resulting hypoxia-induced autophagy then promoted the progression of HCC (Fig. 5A).

Guo et al. discovered that the ubiquitin-binding enzyme UBE2C is highly expressed in patients with non-small cell lung cancer (NSCLC), and UBE2C activation is one of the main factors that drives lung cancer incidence and metastasis [95]. It also reported that the expression of ALKBH5 is high in lung cancer cells. ALKBH5 knockdown reduced the levels of UBE2C, ATG3, and LC3 expression. NSCLC proliferation, clonal development, and invasion depend on the UBE2C-autophagy repression axis (Fig. 5B). In colorectal cancer (CRC), m6A reader protein IGF2BP2 could stabilize MYC mRNA, thus promote glycolysis [96]. As a result, the cellular energy increases, which promotes cellular proliferation. A lncRNA called LINRIS is highly expressed in CRC, which prevents IGF2BP2 destruction via the autophagy ubiquitination pathway [96] (Fig. 5C). The regulatory role of lncRNA in gene transcription and RNA stability has also been reported previously [97]. Patients suffering from melanoma are highly susceptible to developing resistance to conventional anti-cancer therapies. Yang et al. reported that FTO is essential for the progression of melanoma and the development of anti-PD-1 resistance [98]. In melanoma, starvation triggers autophagy and the NF-kB pathway, which in turn activates FTO. Mechanistically, FTO depletion elevates m6A-modification of PD-1, CXCR4, and SOX10 transcripts. Consequently, these transcripts are degraded by YTHDF2. These findings suggest that novel therapeutic strategies for melanoma can be devised by employing anti-PD-1 agents and FTO pathway inhibitory agents (Fig. 5D). Given the results of several studies, it is conceived that m6A modifications and aberrant autophagy regulation could promote the incidence and progression of many types of cancer. Therefore, there is an utmost need to understand the molecular mechanisms which

![Fig. 6](image-url)
promote m6A-autophagy interaction mediated cancer development.

Role of m6A modification and autophagy interplay in cancer drug resistance
Many recent studies exhibited that m6A modification mediated dysregulation of autophagy is well connected to the development of cancer drug resistance (Fig. 6). Gefitinib resistance is the main hurdle in achieving better therapeutic effects in NSCLC. Liu et al. discovered that β-elemene (an anti-cancer drug) could reverse gefitinib resistance through modulating METTL3-mediated autophagy [19]. This study showed that METTL3 could increase the expression of ATG5 and ATG7. Simultaneously, β-elemene attenuated m6A methylation of ATG transcripts by inhibiting METTL3 expression. Subsequently, it resulted in inhibition of autophagic flux and reversing gefitinib resistance in NSCLC (Fig. 6A).

HCC patients frequently receive sorafenib treatment. In the advanced stage of HCC, patients are highly susceptible to developing sorafenib resistance. Lin et al. demonstrated the essential role of METTL3-mediated m6A modification in the hypoxic tumor microenvironment and revealed that FOXO3 is primarily targeted by m6A modification in sorafenib-resistant tumors [51] (Fig. 6B). FOXO3 could reduce the expression of ATG proteins, including ATG5, ATG7, ATG16L1, and MAP1LC3B in HCC. These findings suggest that FOXO3 is vital for achieving m6A-dependent chemo-sensitivity in HCC due to its inhibitory effects on autophagy.

A recent study discovered the increased levels of ARHGAP5-AS1 (a lncRNA) in chemo-resistant gastric cancer (CGC) [99]. Its high expression resulted due to the impaired autophagy. ARHGAP5-AS1 could enhance the expression of ARHGAP5 (chemoresistance promoting gene) by stabilizing ARHGAP5 transcripts in CGC. ARHGAP5-AS1 mainly stabilizes ARHGAP5 mRNA by promoting METTL3-mediated m6A modification (Fig. 6C). These findings reveal that m6A modification and dysregulated autophagy contribute to attaining chemoresistance in CGC.

Taken together, the understanding of the role of m6A-autophagy interaction in cancer chemo-resistance might help in solving many unanswered questions and may provide opportunities to develop novel therapeutic strategies to overcome chemo-resistance in cancer.

Conclusions and prospects
For the first time in 2018, Jin et al. reported a connection between m6A modification and autophagy [13]. Since that time, several studies have been conducted to understand the role of this relationship in various health conditions. Jin et al. showed that FTO knockdown downregulated the ULK1 abundance. Subsequently, it inhibited autophagy. This finding indicates that FTO is a positive regulator of autophagy. Another m6A demethylase, ALKBH5, also positively impacted autophagy [17, 48, 91]. Increased expression of ALKBH5 in NPCs in a coculture model decreased m6A methylation on the FIP200 transcript and stabilized it, which ultimately enhanced the autophagy and inhibited the apoptosis [91]. These research outcomes revealed that both m6A demethylases (FTO and ALKBH5) could positively regulate autophagy and showed that m6A modification is inversely associated with the autophagy process.

Current research data demonstrated that m6A modification could influence autophagy initiation and elongation through regulating the expression of ULK1, FIP200, and ATG5, ATG7, respectively. Moreover, m6A modification was also observed to regulate the AMPK/AKT pathway, which has an essential role in autophagy regulation. m6A modification promotes PPM1A (AMPK negative regulator) expression and impedes the expression of CAMKK2 (AMPK positive regulator). Such alterations contribute to autophagy inhibition [48]. Moreover, reduced m6A modification levels could also activate AKT signaling pathways [100, 101]. AKT pathway is well known for promoting the incidence and progression of various diseases. Therefore, further investigations to explore the dynamic role of m6A modification in regulating the AKT pathway and expression of autophagy-related genes could provide new avenues for future studies.

Since both m6A epigenetic modification and autophagy play crucial roles in cellular and organismal metabolic activities, many studies conducted to explore the m6A-autophagy interaction in various human diseases (Table 1). m6A-autophagy interactivity could influence adipogenesis and testosterone synthesis, and induce obesity and male fertility disorders, respectively. Moreover, the m6A-autophagy interaction could induce apoptosis in cardiomyocytes and nucleus pulposus cells, which can cause ischemic heart disease and IVD degeneration, respectively. Given the vital role of autophagy in the onset of CVDs, further exploration of autophagy-related signaling pathways is needed. In addition, investigation of the regulatory role of m6A-autophagy interplay in cancer onset (such as liver cancer, gastric cancer, lung cancer) and cancer drug resistance is currently a popular area of research. Novel findings in this research area could help in devising treatment strategies to overcome cancer-related problems.

Recently, Wang et al. conducted a study in leukocytes collected from chronic kidney disease (CKD) patients. In this study, leukocytes exhibited decreased m6A modification levels. The reason for this outcome was the increased
demethylase activity of FTO [102]. The FTO-mediated
downregulation of m6A could have influenced the
autophagy process in leukocytes. The resulting impair-
ment might have contributed to disrupting normal kid-
ney functions because autophagy plays a critical role
in the physiological functions of the kidney[103]. Therefore,
it is necessary to identify molecules that could regulate
m6A modification and autophagy to improve leukocyte
functions in CKD.

m6A modification is the most significant internal epi-
genetic modification in eukaryotic mRNA and highly
enriched in brain tissue [23, 104]. It is also reported that
m6A could regulate the physiological functions of the
mammalian nervous system, including synaptic plasticity,
learning, and memory [105, 106]. A genome-wide association study (GWAS) revealed that m6A dysfunction is linked to developing neurological disorders [107]. Furthermore, several studies have confirmed the role of m6A modification in the development of these disorders [108, 109]. Altered m6A regulation could play an important role in the occurrence of Alzheimer’s disease and its associated dementia [110, 111]. Chen et al. revealed a critical role of m6A modification in developing Parkinson’s disease (PD) [112]. Qiu et al. reported that m6A-associated single nucleotide polymorphisms could increase the risk of PD incidence [113]. Literature review indicates that impaired autophagy could result in the aggregation of misfolded proteins, which is considered a hallmark of neurodegenerative diseases [114, 115]. Therefore, data have showed that both m6A modification and autophagy could play a substantial role in the onset of neurodegenerative diseases respectively. In the future, it is important to investigate the role of the m6A-autophagy axis in the incidence and progression of neurodegenerative diseases. It could help for better understandings in the development and treatment of neurological disorders.

The relationship between m6A and autophagy has been investigated in many human disorders, but findings are still limited to make comprehensive inferences. Further research is needed to decipher the exact role of m6A-autophagy interplay in the incidence of various pathological conditions. The resulting data could help understand molecular mechanisms exploited by m6A-autophagy interaction to induce human disorders. These findings could also offer the possibility of developing novel therapeutic strategies to overcome m6A-autophagy interaction mediated human disorders.

Abbreviations
ALKBH5: Alpha-ketoglutarate-dependent dioxygenase alkB homolog 5; ALP: Adenosine 5-monophosphate-activated protein kinase; ATG: Autophagy-related; BMSCs: Bone marrow-derived mesenchymal stem cells; CGC: Chemo-resistant gastric cancer; CKD: Chronic kidney disease; CMA: Chaperone-mediated autophagy; CRC: Colorectal cancer; CVDs: Cardiovascular diseases; FIP200: Focal adhesion kinase family interacting protein of 200 kDa; FoxO3: Forkhead box class O3; FTO: Fat mass and obesity associated; HCC: Human hepatocellular carcinoma; HNRNPD: RNA binding protein of 200 kDa; HNRNPD: RNA binding protein heterogeneous nuclear ribonucleoprotein D; IGF2BP: Insulin-like growth factor 2 mRNA-binding proteins; iNDE: Intervertebral disc; LAMP-2A: Lysosomal-associated membrane protein 2A; lncRNAs: Long non-coding RNAs; m6A: N6-methyladenosine; METTL3: Methyltransferase-like 3; METTL14: Methyltransferase-like 14; mTOR: Mammalian target of rapamycin; mTORC1: Rapamycin complex 1; NPCS: Nucleus pulposus cells; NSCLC: Non-small cell lung cancer; PI3K: Phosphatidylinositol 3-kinase; RBM15: RNA binding motif protein 15; TFE3: Transcription factor EB; ULK1/2: Unc-51 like kinase 1/2; WTPAP: Wilms’ tumor 1-associated protein; YTHDC1-2: YTH domain-containing proteins 1-2; YTHDF1-3: YTH domain-containing family proteins 1-3.

Acknowledgements
Not applicable.

Authors’ contributions
The idea for the article was raised by JW and ZL. The first draft of the manuscript was written by XC and JW. XC performed the literature search and data analysis. MT, FZ, and YR revised the work.

Funding
This work was supported by the National Natural Science Foundation of China (No. 91854115, 31970044, 31771571 to JW, and No. 81400935 to XC), the Beijing Municipal Natural Science Foundation (No.7202001 to XC), and the Scientific Research Project of Beijing Educational Committee (No. KM20201005022 to XC).

Availability of data and material
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
All authors declare that they have no conflict of interest.

Received: 23 April 2021 Accepted: 19 July 2021

Published online: 27 July 2021

References
1. Levine B, Kroemer G. Biological functions of autophagy genes: a disease perspective. Cell. 2019;176(1-2):11–42.
2. Mizushima N, Levine B. Autophagy in human diseases. N Engl J Med. 2020;383(16):1564–76.
3. Leidal AM, Levine B, Debnath J. Autophagy and the cell biology of age-related disease. Nat Cell Biol. 2018;20(12):1338–48.
4. Saftig P, Beertsen W, Eskelinen EL. LAMP-2: a control step for phagosome and autophagosome maturation. Autophagy. 2008;4(4):510–2.
5. He C, Klonsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009;43:67–93.
6. Levine B, Klonsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6(4):463–77.
7. Klonsky DJ, Ern SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290(5497):1717–21.
8. Yorimitsu T, Klonsky DJ. Autophagy: molecular machinery for self-eating. Cell Death Differ. 2005;12(Suppl 2):1542–52.
9. Saha S, Panighrahi DP, Patil S, Bhutia SK. Autophagy in health and disease: a comprehensive review. Biomed Pharmacother. 2018;104:485–95.
10. Sui X, Zhu J, Zhou J, Wang X, Li D, Han W, et al. Epigenetic modifications as regulatory elements of autophagy in cancer. Cancer Lett. 2015;360(2):106–13.
11. Bhol CS, Panighrahi DP, Praharaj PP, Mahapatra KK, Patra S, Mishra SR, et al. Epigenetic modifications of autophagy in cancer and cancer therapeutics. Semin Cancer Biol. 2020;66:22–33.
12. Chen X, Sun YZ, Liu H, Zhang L, Li QJ, Meng J. RNA methylation and diseases: experimental results, databases, Web servers and computational models. Brief Bioinform. 2019;20(5):896–917.
13. Jin S, Zhang X, Maio Y, Liang P, Zhu K, She Y, et al. m(6)A RNA modification controls autophagy through upregulating ULK1 protein abundance. Cell Res. 2018;28(9):955–7.
14. Li B, Jiang J, Assaraf YG, Xiao H, Chen ZS, Huang C. Surmounting cancer drug resistance: new insights from the perspective of N(6)-methyladenosine RNA modification. Drug Resist Updat. 2020;33:100720.
15. Chen J, Wang C, Fei W, Fang X, Hu X. Epitranscriptomic m6A modification in the stem cell field and its effects on cell death and survival. Am J Cancer Res. 2019;9(4):752–64.
16. Liu S, Li Q, Chen K, Zhang Q, Li G, Zhuo L, et al. The emerging molecular mechanism of m(6)A modulators in tumorigenesis and cancer progression. Biomed Pharmacother. 2020;127:110098.

17. Song H, Feng X, Zhang H, Luo Y, Huang J, Lin M, et al. METTL3 and ALKBHS oppositely regulate m(6)A modification of TFE3 mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes. Autophagy. 2019;15(8):1419–37.

18. Wang X, Wu R, Liu Y, Zhao Y, Bi Z, Yao Y, et al. m(6)A RNA methylation controls autophagy and adipogenesis by targeting Atg5 and Atg7. Autophagy. 2020;16(7):1212–33.

19. Liu S, Li Q, Li G, Zhang Q, Zhuo L, Han X, et al. The mechanism of m(6)A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by beta-ellipse. Cell Death Dis. 2020;11(11):1699.

20. Meyer KD, Jaffrey SR. The dynamic epitranscriptome: N6-methyladenosine mediates mRNA translation and mediates the fate of hypoxia/reoxygenation-treated cardiomyocytes. Nat Commun. 2016;7:12626.

21. Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, et al. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017;27(3):315–28.

22. Li A, Chen YS, Ping XL, Yang X, Xiao W, Yang Y, et al. Cytoplasmic m(6)A reader YTHDF3 promotes mRNA translation. Cell Res. 2017;27(3):444–7.

23. Roundtree IA, Luo QZ, Zhang Z, Wang X, Zhou T, Cui Y, et al. YTHDC1 mediates nuclear export of N(6)-methyladenosine methylated mRNAs. Elife. 2017;6:e31311.

24. Roundtree IA, He C. Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. Trends Genet. 2016;32(6):320–1.

25. Hsu PI, Zhu Y, Ma H, Guo Y, Shi X, Liu Y, et al. YTHDC2 is an N(6)-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017;27(9):1115–27.

26. Huang H, Heng W, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N(6)-methyladenosine by IGFBP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285–95.

27. Piya S, Andreeff M, Borthakur G. Targeting autophagy to overcome chemoresistance in acute myelogenous leukemia. Autophagy. 2017;13(1):214–5.

28. Zhitomirsky B, Assaraf YG. Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget. 2015;6(2):1143–56.

29. Chen Y, Wang J, Xu D, Xiang Z, Ding J, Yang X, et al. m(6)A mRNA methylation regulates testesosterone synthesis through modulating autophagy in Leydig cells. Autophagy. 2021;17(2):457–75.

30. Tang HW, Weng JH, Lee WX, Hu Y, Gu L, Cho S, et al. mTORC1-chaperonin CCT signaling regulates m(6)A mRNA methylation to suppress autophagy. Proc Natl Acad Sci U S A. 2021;118(10):e2021945118.

31. Zhu H, Can X, Jiang X, Dao S, Wu H, Hu J. ALKBH5 inhibited autophagy of epithelial ovarian cancer through m(6)A-BCL-2. J Exp Clin Cancer Res. 2019;38(1):163.

32. Lin Z, Ni Y, Wan A, Chen D, Liang H, Chen X, et al. RNA (m)6-A methyltransferase regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 2020;39(12):e103181.

33. Puertollano R, Ferguson SH, Brugarolas J, Ballabio A. The complex relationship between TFE3 transcription factor phosphorylation and subcellular localization. EMBO J. 2018;37(11):e98804.

34. Sung H, Siegel RL, Torre LA, Pearson-Stuttard J, Islami F, Fedewa SA, et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. 2018;69(2):88–112.

35. Choo YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:10–8.

36. Rosen ED, MacDougall OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol. 2006;7(12):885–96.

37. Zhao X, Yang Y, Sun BF, Shi Y, Yang X, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell Res. 2014;24(12):1403–19.

38. Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, et al. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015;161(6):1388–99.

39. Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, et al. YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. Nat Commun. 2016;7:12626.

40. Piya S, Andreeff M, Borthakur G. Targeting autophagy to overcome chemoresistance in acute myelogenous leukemia. Autophagy. 2017;13(1):214–5.

41. Zhitomirsky B, Assaraf YG. Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget. 2015;6(2):1143–56.

42. Chen Y, Wang J, Xu D, Xiang Z, Ding J, Yang X, et al. m(6)A mRNA methylation regulates testesosterone synthesis through modulating autophagy in Leydig cells. Autophagy. 2021;17(2):457–75.

43. Tang HW, Weng JH, Lee WX, Hu Y, Gu L, Cho S, et al. mTORC1-chaperonin CCT signaling regulates m(6)A mRNA methylation to suppress autophagy. Proc Natl Acad Sci U S A. 2021;118(10):e2021945118.

44. Zhu H, Can X, Jiang X, Dao S, Wu H, Hu J. ALKBH5 inhibited autophagy of epithelial ovarian cancer through m(6)A-BCL-2. J Exp Clin Cancer Res. 2019;38(1):163.

45. Lin Z, Ni Y, Wan A, Chen D, Liang H, Chen X, et al. RNA (m)6-A methyltransferase regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 2020;39(12):e103181.

46. Puertollano R, Ferguson SH, Brugarolas J, Ballabio A. The complex relationship between TFE3 transcription factor phosphorylation and subcellular localization. EMBO J. 2018;37(11):e98804.

47. Sung H, Siegel RL, Torre LA, Pearson-Stuttard J, Islami F, Fedewa SA, et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. 2018;69(2):88–112.

48. Choo YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:10–8.

49. Rosen ED, MacDougall OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol. 2006;7(12):885–96.

50. Zhao X, Yang Y, Sun BF, Shi Y, Yang X, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell Res. 2014;24(12):1403–19.

51. Wang X, Sun B, Jiang Q, Wu R, Cai M, Yao Y, et al. mRNA m(6)A plays opposite role in regulating UCP2 and PNP/LA2 protein expression in adipocytes. Int J Obes (Lond). 2018;42(11):1912–24.

52. Wang X, Zhu L, Chen J, Wang Y. mRNA m(6)A methylation downregulates adipogenesis in porcine adipocytes. Biochem Biophys Res Commun. 2015;459(2):201–7.

53. Wu R, Liu Y, Yao Y, Zhao Y, Bi Z, Jiang Q, et al. FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863(10):1323–30.
post-transcriptional regulation to promote adipogenic differentiation.

Nucleic Acids Res. 2019;47(12):6130–44.

62. Singh R, Xiang Y, Wang Y, Baikati K, Cuevo AM, Luu YK, et al. Autophagy regulates adipose mass and differentiation in mice. J Clin Invest. 2009;119(11):3529–39.

63. Yamamoto T, Takabayake T, Takashashi A, Kimura T, Namba T, Matsuda J, et al. High-fat diet-induced lysosomal dysfunction and impaired autophagic flux contribute to lipotoxicity in the kidney. J Am Soc Nephrol. 2017;28(5):1534–51.

64. Liu J, Javaheri A, Godar RJ, Murphy J, Ma X, Rohatgi N, et al. Intermittent fasting promotes beta-cell mass in obesity-induced diabetes via the autophagy-lysosome pathway. Autophagy. 2017;13(1):1952–68.

65. Codogno P, Meijer AJ. Autophagy: a potential link between obesity and insulin resistance. Cell Metab. 2010;11(6):449–51.

66. Mizunoe Y, Sudo Y, Okita N, Hiroaki H, Mikami K, Narahara T, et al. Involvement of lysosomal dysfunction in autophagosome accumulation and early pathologies in adipose tissue of obese mice. Autophagy. 2017;13(4):642–53.

67. Cheung MK, Gulati P, O’Rahilly S, Yeo GS. FTO expression is regulated by obesity-related FTO gene in the cellular sensing of amino acids. Proc Natl Acad Sci U S A. 2013;110(7):2557–62.

68. Pekna M, Card there M. RNA epigenetics and cardiometabolic risk: implications for human health and disease. Nucleic Acids Res. 2019;47(12):6130–44.

69. Gulati P, Cheung MK, Antrobus R, Church CD, Harding HP, Tung YC, et al. Role for the obesity-related FTO gene in the cellular sensing of amino acids. Proc Natl Acad Sci U S A. 2013;110(7):2557–62.

70. Aas A, Isakson P, Bindesboll C, Alemu EA, Klungland A, Simonsen A. ATG12~ATG5 conjugate required for LC3 lipidation in autophagy. Nat Struct Mol Biol. 2013;20(1):59–66.

71. Wesselborg S, Stork B. Autophagy signal transduction by ATG proteins: from hierarchies to networks. Cell Mol Life Sci. 2015;72(24):4721–57.

72. Otomo C, Metlagel Z, Takaesu G, Otomo T. Structure of the human ATG12~ATG5 conjugate required for LC3 lipidation in autophagy. Nat Struct Mol Biol. 2013;20(1):59–66.

73. Kleene KC. Connecting cis-elements and trans-factors with mechanisms of transcription and early pathologies in adipose tissue of obese mice. Autophagy. 2017;13(4):642–53.

74. Cheung MK, Gulati P, O’Rahilly S, Yeo GS. FTO expression is regulated by availability of essential amino acids. Int J Obes (Lond). 2013;37(5):745–7.

75. Yeo GS. The role of the FTO (Fat Mass and Obesity Related) locus in the cellular sensing of amino acids. Proc Natl Acad Sci U S A. 2013;110(7):2557–62.

76. Qin Y, Li L, Luo E, Hou J, Yan G, Wang D, et al. Role for the obesity-related FTO gene in the cellular sensing of amino acids. Proc Natl Acad Sci U S A. 2013;110(7):2557–62.

77. Li WR, Chen L, Chang ZJ, Xin H, Liu T, Zhang YQ, et al. Autophagic deficiency promotes tumorigenesis and cell survival in endometrioid endometrial cancer. Nat Cell Biol. 2018;20(9):1074–83.

78. Chen XY, Zhang J, Zhu JS. The role of m6A mRNA methylation in human cancer. Mol Cancer. 2019;18(1):103.

79. Chen J, Xie JJ, Jin MY, Gu YT, Wu CC, Guo WJ, et al. Sirt1 overexpression suppresses senescence and apoptosis of nucleus pulposus cells by inducing autophagy in a mouse model of intervertebral disc degeneration. Cell Death Dis. 2018;9(2):56.

80. Lin Z, Tong MH. m6A mRNA modification regulates mammalian spermatogenesis. Front Mol Biosci. 2020;7:555372.

81. Chen J, Xie JJ, Jin MY, Gu YT, Wu CC, Guo WJ, et al. Sirt1 overexpression suppresses senescence and apoptosis of nucleus pulposus cells by inducing autophagy in a mouse model of intervertebral disc degeneration. Cell Death Dis. 2018;9(2):56.

82. Qin Y, Li L, Luo E, Hou J, Yan G, Wang D, et al. Loss of function of transcription factor EB promotes lipid metabolism and cell death pathways in the cardiomyocyte. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165832.

83. Chen J, Xie JJ, Jin MY, Gu YT, Wu CC, Guo WJ, et al. Sirt1 overexpression suppresses senescence and apoptosis of nucleus pulposus cells by inducing autophagy in a mouse model of intervertebral disc degeneration. Cell Death Dis. 2018;9(2):56.

84. Li G, Song Y, Liao Z, Wang K, Luo R, Lu S, et al. Bone-derived mesenchymal stem cells alleviate compression-induced apoptosis of nucleus pulposus cells by N6-methyladenosine of autophagy. Cell Death Dis. 2020;11(2):103.

85. Chen XY, Zhang J, Zhu JS. The role of m6A mRNA methylation in human cancer. Mol Cancer. 2019;18(1):103.

86. Saito T, Nah J, Oka SI, Mukai R, Monden Y, Maejima Y, et al. An alternative miophathy pathway mediated by Rab8b protects the heart against ischemia. J Clin Invest. 2019;129(2):802–19.

87. Mathiyalagan P, Adamakia M, Mayouarian J, Sassi Y, Liang Y, Agarwal N, et al. FTO-dependent N6-methyladenosine regulates cardiac function during remodeling and repair. Circulation. 2019;139(4):518–32.

88. Ma X, Mani K, Liu H, Kovacs A, Murphy JT, Foroughi L, et al. Transcription factor EB activation rescues advanced alphab-crystallin mutation-induced cardiomyopathy by normalizing desmin localization. J Am Heart Assoc. 2019;8(4):e010866.

89. Trivedi PC, Bartlett JJ, Mercer A, Slade L, Sutteze M, Ballabio A, et al. Loss of function of transcription factor EB modulates lipid metabolism and cell death pathways in the cardiomyocyte. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165832.

90. Chen J, Xie JJ, Jin MY, Gu YT, Wu CC, Guo WJ, et al. Sirt1 overexpression suppresses senescence and apoptosis of nucleus pulposus cells by inducing autophagy in a mouse model of intervertebral disc degeneration. Cell Death Dis. 2018;9(2):56.
109. Engel M, Chen A. The emerging role of mRNA methylation in normal and pathological behavior. Genes Brain Behav. 2018;17(3):e12428.
110. Han M, Liu Z, Xu Y, Liu X, Wang D, Li F, et al. Abnormality of m6A mRNA methylation is involved in Alzheimer’s disease. Front Neurosci. 2020;14:98.
111. Huang H, Camats-Perna J, Medeiros R, Anggono V, Widagdo J. Altered expression of the m6A methyltransferase METTL3 in Alzheimer’s disease. eNeuro. 2020. https://doi.org/10.1523/ENEURO.0125-20.2020.
112. Chen X, Yu C, Guo M, Zheng X, Ali S, Huang H, et al. Down-regulation of m6A mRNA methylation is involved in dopaminergic neuronal death. ACS Chem Neurosci. 2019;10(5):2355–63.
113. Qiu X, He H, Huang Y, Wang J, Xiao Y. Genome-wide identification of m(6)A-associated single-nucleotide polymorphisms in Parkinson’s disease. Neurosci Lett. 2020;737:135315.
114. Guo F, Liu X, Cai H, Le W. Autophagy in neurodegenerative diseases: pathogenesis and therapy. Brain Pathol. 2018;28(1):3–13.
115. Luo R, Su LY, Li G, Yang J, Liu Q, Yang LX, et al. Activation of PPARα-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. Autophagy. 2020;16(1):52–69.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.